Skip to main content

What the FDA labels say about taking them together

Rosuvastatin and ticagrelor

Rosuvastatin's FDA label of September 4, 2026 names ticagrelor in its drug interactions section, and ticagrelor's label names rosuvastatin too. The rosuvastatin label: “Mechanism and Clinical Effect (s): Ticagrelor increased rosuvastatin exposure by 2.3-fold.”

Check it at the source: the rosuvastatin FDA label on DailyMed (effective September 4, 2026, ScieGen Pharmaceuticals, Inc.); the ticagrelor FDA label on DailyMed (effective May 7, 2026, AstraZeneca Pharmaceuticals LP).

What does the rosuvastatin label say about ticagrelor?

Rosuvastatin label, drug interactions

Mechanism and Clinical Effect (s): Ticagrelor increased rosuvastatin exposure by 2.3-fold.

Source: FDA drug label (Rosuvastatin), ScieGen Pharmaceuticals, Inc., effective September 4, 2026 (SPL set ee4933c5-0d97-494d-ac0f-2083e0100836), via openFDA; the full label on DailyMed

What does the ticagrelor label say about rosuvastatin?

Ticagrelor label, drug interactions

Rosuvastatin plasma concentrations may increase. Monitor for statin-related adverse effects.

Source: FDA drug label (BRILINTA), AstraZeneca Pharmaceuticals LP, effective May 7, 2026 (SPL set f7b3f443-e83d-4bf2-0e96-023448fed9a8), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

45Rosuvastatin generic labelers
28Ticagrelor generic labelers
RosuvastatinTicagrelor
Labeled forHeart attack and coronary artery disease, High cholesterol, High triglycerides, Stroke preventionHeart attack and coronary artery disease, Stroke prevention
Boxed warningNoYes
Pharmacy cost (NADAC)$0.0692 per tablet 40 mg tablet$0.253 per tablet 90 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?